KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Non-Current Assets: 2011-2025

Historic Other Non-Current Assets for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to $62.4 million.

  • Supernus Pharmaceuticals' Other Non-Current Assets was N/A to $62.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.4 million, marking a year-over-year change of. This contributed to the annual value of $31.5 million for FY2024, which is 15.94% down from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Other Non-Current Assets is $62.4 million, which was up 123.27% from $28.0 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Other Non-Current Assets peaked at $403.8 million during Q1 2023, and registered a low of $28.0 million during Q2 2025.
  • Moreover, its 3-year median value for Other Non-Current Assets was $37.9 million (2023), whereas its average is $74.4 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Other Non-Current Assets surged by 5,523.98% in 2021, and later tumbled by 90.50% in 2024.
  • Supernus Pharmaceuticals' Other Non-Current Assets (Quarterly) stood at $49.2 million in 2021, then fell by 19.15% to $39.8 million in 2022, then decreased by 5.78% to $37.5 million in 2023, then decreased by 15.94% to $31.5 million in 2024, then decreased by 22.09% to $62.4 million in 2025.
  • Its last three reported values are $62.4 million in Q3 2025, $28.0 million for Q2 2025, and $29.2 million during Q1 2025.